CD27 Antibodies

Background

CD27 is a cell surface glycoprotein belonging to the tumor necrosis factor receptor superfamily (TNFRSF), mainly expressed on the surface of immune cells such as T cells, B cells and natural killer cells. As an important costimulatory molecule, CD27 participates in lymphocyte activation, proliferation and differentiation by binding to the ligand CD70, and plays a key role in adaptive immune response and immune memory formation. This gene was first identified by the team of Dutch scientist Rene van Lier in 1987. Its unique structural features include an extracellular region rich in cysteine and an intracellular TRAF2 binding domain. This structural design enables it to effectively conduct immune activation signals. The discovery of the CD27/CD70 signaling pathway not only deepens people's understanding of the immune regulatory mechanism, but also provides an important target for tumor immunotherapy and autoimmune disease research. Currently, antibody drugs based on this pathway have entered the clinical trial stage.

Structure Function Application Advantage Our Products

Structure of CD27

CD27 is a transmembrane glycoprotein with a molecular weight of approximately 50-55 kDa, belonging to the tumor necrosis factor receptor superfamily (TNFRSF). There are certain differences in its molecular weight among different species:

Species	Human	Mouse	Rhesus monkey
Molecular Weight (kDa)	50-55	48-52	52-55

CD27 stabilizes its extracellular domain through disulfide bonds, while the conserved sequence "QEE" in the intracellular segment is crucial for recruiting TRAF-adapted proteins, thereby activating signaling pathways such as NF-κB to regulate immune responses.

Fig. 1:Proposed models of binding of the hCD27 monoclonal antibody determined by in silico docking analysis. Fig. 1 Proposed models of binding of the hCD27 mAb determined by in silico docking analysis.¹

Key structural properties of CD27:

Typical folded structure of the TNF receptor superfamily
Four conserved cysteine-rich domains (CRD1-4) form ligand binding interfaces
Intracellular section contains specific TRAF protein combined with the base sequence (QEE)
Across the membrane area to maintain stability of receptor alpha helix structure

Functions of CD27

The main function of CD27 is to regulate the activation of immune cells as a costimulatory molecule, and it also plays a key role in maintaining immune homeostasis and the formation of memory cells.

Function	Description
T-cell co-stimulation	By binding to CD70, it provides a second signal to promote T cell proliferation and cytokine secretion.
Regulation of B cell differentiation	Participates in the germinal center response and regulates the differentiation of B cells into plasma cells and memory B cells.
Immune memory formation	For long-term memory T cells and B cells play an important role.
Tumor immune surveillance	Enhance the anti-tumor immune response by activating cytotoxic T cells.
Autoimmune regulation	Dysregulated CD27 signaling may lead to the occurrence of autoimmune diseases.

This precise regulatory mechanism makes CD27 a key molecule connecting innate immunity and adaptive immunity, and its functional abnormalities are closely related to diseases such as tumor immune escape, autoimmune diseases and immune deficiencies.

Applications of CD27 and CD27 Antibody in Literature

1. Gong, Lanqi, et al. "Nasopharyngeal carcinoma cells promote regulatory T cell development and suppressive activity via CD70-CD27 interaction." Nature Communications 14.1 (2023): 1912. https://doi.org/10.1038/s41467-023-37614-6

The article highlights myoglobin as a key factor in rhabdomyolysis-induced acute kidney injury and introduces a high-affinity recombinant rabbit anti-myoglobin monoclonal antibody with broad species reactivity and strong diagnostic potential, potentially serving as a neutralizing antibody for RM-related diseases.

2. Lutfi, Forat, et al. "Targeting the CD27-CD70 pathway to improve outcomes in both checkpoint immunotherapy and allogeneic hematopoietic cell transplantation." Frontiers in Immunology 12 (2021): 715909. https://doi.org/10.3389/fimmu.2021.715909

This article explores the potential of the CD27-CD70 co-stimulation pathway in immunotherapy: 1) Combining with immune checkpoint inhibitors to enhance anti-tumor efficacy; 2) As a new strategy for the prevention of graft-versus-host disease (GVHD). The research focuses on the immune mechanism in the early mixed chimeric stage of GVHD, providing ideas for the novel prevention and treatment of GVHD.

3. Bowakim-Anta, Natalia, et al. "Chronic CD27-CD70 costimulation promotes type 1-specific polarization of effector Tregs." Frontiers in immunology 14 (2023): 1023064. https://doi.org/10.3389/fimmu.2023.1023064

Studies have shown that the CD27 co-stimulatory signal can autonomously activate regulatory T cells (Tregs), promote the polarization of conventional CD4+ T cells towards Th1, enhance the IFN-γ response and CXCR3-mediated inflammatory chemotaxis. This discovery reveals that CD27 may regulate the peripheral Th1 immune response and memory formation.

4. Tao, Yanling, et al. "LncRNA CD27-AS1 promotes acute myeloid leukemia progression through the miR-224-5p/PBX3 signaling circuit." Cell Death & Disease 12.6 (2021): 510. https://doi.org/10.1038/s41419-021-03767-9

Studies have found that lncRNA CD27-AS1 is highly expressed in acute myeloid leukemia (AML) and is associated with a poor prognosis. Mechanistically, CD27-AS1 upregulates the expression of PBX3 by adsorbing miR-224-5p and activates the MAPK pathway to promote the proliferation of AML cells, suggesting that it can serve as a potential prognostic marker and therapeutic target.

5. Popova, Anna, et al. "IgA class-switched CD27- CD21+ B cells in IgA nephropathy." Nephrology Dialysis Transplantation 40.3 (2025): 505-515. https://doi.org/10.1093/ndt/gfae173

Research has found that there are abnormally expanded subsets of IgA+CD27-B cells in the peripheral blood of patients with IgA nephropathy (IgAN), and these cells are associated with plasma blasts that secrete galactose-deficient IgA1 (GdIgA1). Research suggests that mucosal immune dysregulation may activate CD27-B cells through germinal centers, promoting the onset of IgAN and providing a new direction for disease mechanisms and treatment.

Creative Biolabs: CD27 Antibodies for Research

Creative Biolabs specializes in the production of high-quality CD27 antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

Custom CD27 Antibody Development: Tailor-made solutions to meet specific research requirements.
Bulk Production: Large-scale antibody manufacturing for industry partners.
Technical Support: Expert consultation for protocol optimization and troubleshooting.
Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our CD27 antibodies, custom preparations, or technical support, contact us at email.

Reference

Heckel, Franziska, et al. "Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering." Communications Biology 5.1 (2022): 229. https://doi.org/10.1038/s42003-022-03182-6